Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Aulos Bioscience’s Imneskibart With Avelumab Delivers Exceptional Progression-Free Survival in Checkpoint Inhibitor-Refractory Adenocarcinoma Non-Small Cell Lung Cancer
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today presented positive Phase 2 data for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The data were shared in a poster session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The...
-
Metropolitan Commercial Bank Earns Great Place To Work® Certification™ for Second Consecutive Year
NEW YORK--(BUSINESS WIRE)--Metropolitan Commercial Bank (“MCB” or the “Bank”), a full-service commercial bank headquartered in New York City, is proud to announce that it has been Certified™ by Great Place To Work® for the second year in a row, reaffirming the Bank's commitment to fostering an exceptional workplace culture where employees feel valued, supported, and empowered to succeed. Great Place To Work® is the global authority on workplace culture, employee experience, and the leadership b...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Genius Sports to Announce Third Quarter 2026 Results on November 5
LONDON & NEW YORK--(BUSINESS WIRE)--Genius Sports Limited (“Genius Sports”) (NYSE:GENI) today announced that it will release its third quarter 2026 results before 8:00AM ET on Thursday, November 5, 2026. At 8:00AM ET on the same day, Genius Sports will host a conference call to discuss the results. Genius Sports’ earnings press release and related materials will be available at investors.geniussports.com. To listen to the live audio webcast and Q&A, please visit Genius Sports’ investor rela...
-
Jack in the Box Announces Fourth Quarter and Full-Year 2026 Earnings Webcast
SAN DIEGO--(BUSINESS WIRE)--Jack in the Box Inc. (NASDAQ: JACK) today announced that it will report fourth quarter and full-year fiscal 2026 financial results after market close on Wednesday, December 9, 2026. The Company will host a conference call and webcast to discuss the results at 5:00 p.m. ET that same day. The live webcast will be available on the Jack in the Box investor relations website at investors.jackinthebox.com, where a replay will also be available following the event. The timi...
-
RyCarma Announces First Patient Dosed in Phase 2 Clinical Trial of Surlorian for the Treatment of RYR1-Related Myopathy
BOSTON--(BUSINESS WIRE)--RyCarma Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class small molecule therapeutics for skeletal muscle diseases, today announced that the first patient was dosed in a Phase 2 clinical trial of surlorian in patients with RYR1-related myopathy (RYR1-RM). RYR1-RM is caused by a mutation in the RYR1 gene and is one of the most prevalent congenital skeletal muscle disorders. The disease is characterized by impaired muscle contraction, we...
-
Builders FirstSource Annual Charity Event Raises $1.6 Million for Blood Cancer United
IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource (NYSE: BLDR) today announced that its 2026 charity event raised approximately $1.6 million for Blood Cancer United. This marks the 20th year of the Builders FirstSource partnership with Blood Cancer United, which has helped raise more than $19 million for critical research, patient support, and advocacy programs dedicated to advancing treatments and cures for blood cancers over those two decades. Held Sept. 30-Oct. 1 in Irving, Texas, the eve...
-
Alliance Resource Partners, L.P. Reports Third Quarter 2026 Financial and Operating Results; Declares Quarterly Cash Distribution of $0.60 Per Unit; and Updates Guidance
TULSA, Okla.--(BUSINESS WIRE)--Alliance Resource Partners, L.P. Reports 3rd Quarter 2026 Financial and Operating Results; Declares Quarterly Distribution of $0.60; Updates Guidance...
-
First Farmers and Merchants Corporation Reports Third Quarter Net Income Up 12.7% to $5.5 Million
COLUMBIA, Tenn.--(BUSINESS WIRE)--First Farmers and Merchants Corporation (OTCID: FFMH), the holding company for First Farmers and Merchants Bank, today announced its results for the third quarter of 2026, reflecting continued growth and profitability, including robust 24.4% annualized loan growth, a 12.7% increase in net income, and an eleventh consecutive quarter of net interest margin expansion. “What stood out in our third quarter was the sheer execution and dedication of our banking teams...